Anika Therapeutics, INC Form 4 insider transactions

CEO Stephen D. Griffin acquired 12,840 shares of Anika Therapeutics common stock through the vesting of restricted stock units.

Anika Therapeutics Director John B. Henneman III has acquired 5,000 shares of common stock.

President and CEO Stephen D. Griffin purchased 12,200 shares of Anika Therapeutics common stock on April 30, 2026.

Anika Therapeutics, Inc. granted Restricted Stock Units and Premium Priced Stock Appreciation Rights to SVP, CAO & Treasurer Ian McLeod, aligning executive incentives with long-term shareholder value.

Anika Therapeutics' EVP, General Counsel, and Corporate Secretary, David Colleran, reported the vesting of restricted stock units and performance-based units, along with associated tax withholdings.

Anika Therapeutics CEO Stephen D. Griffin reported the vesting of restricted stock units and performance stock units, alongside shares withheld for tax obligations.

Anika Therapeutics Director Cheryl R. Blanchard reported the vesting and tax-related disposition of restricted stock units and performance-based units.

Anika Therapeutics' SVP, CAO & Treasurer Ian McLeod reported the vesting of restricted stock units and performance-based phantom units, alongside associated tax withholdings.

Anika Therapeutics' President and CEO, Stephen D. Griffin, was granted 310,207 Stock Appreciation Rights and 130,402 Restricted Stock Units, alongside existing common stock holdings.

Anika Therapeutics, Inc. Director Susan L.N. Vogt was granted 14,164 restricted stock units (RSUs) on June 20, 2025, increasing her beneficial ownership to 50,213 shares.

Anika Therapeutics, Inc. Director Stephen Richard was granted 14,164 restricted stock units, increasing his beneficial ownership to 47,871 shares.

Anika Therapeutics, Inc. Director Glenn R. Larsen has been granted 14,164 restricted stock units (RSUs) which will vest in 2026, increasing his beneficial ownership to 50,258 shares.

Anika Therapeutics, Inc. Director William R. Jellison reported the acquisition of 14,164 restricted stock units (RSUs) as part of his compensation, vesting by June 2026.

Anika Therapeutics, Inc. Director John B. Henneman III was granted 14,164 restricted stock units (RSUs) on June 20, 2025, as part of his compensation, aligning his interests with shareholder value.

Anika Therapeutics, Inc. Director Gary P. Fischetti was granted 14,164 restricted stock units (RSUs) on June 20, 2025, which will vest by June 2026.

Anika Therapeutics, Inc. Director Sheryl L. Conley was granted 14,164 restricted stock units (RSUs) on June 20, 2025, as part of her compensation, aligning her interests with shareholders.

Anika Therapeutics, Inc. Director Joseph H. Capper was granted 14,164 restricted stock units (RSUs) on June 20, 2025, increasing his beneficial ownership to 20,403 shares.

Stephen D. Griffin, Anika Therapeutics' EVP, CFO & COO, reported the vesting of 12,840 Restricted Stock Units and related share transactions, including tax withholding, on June 3, 2025.

Anne Nunes, SVP and Chief Operations Officer of Anika Therapeutics, reports the vesting of restricted stock units and associated tax withholding.

Stephen D. Griffin, EVP, CFO, and Treasurer of Anika Therapeutics, reports the acquisition of restricted stock units (RSUs) on March 14, 2025.

David Colleran, EVP, General Counsel, and Corporate Secretary of Anika Therapeutics, reports transactions involving common stock and restricted stock units.

Cheryl Blanchard, CEO of Anika Therapeutics, reports the vesting of RSUs and related stock transactions.

Anne Nunes, SVP and Chief Operations Officer of Anika Therapeutics, reports the vesting of RSUs and subsequent stock transactions.

David Colleran, EVP, General Counsel, and Corporate Secretary of Anika Therapeutics, reports the vesting of RSUs and subsequent stock transactions to cover tax obligations.

Cheryl Blanchard, CEO of Anika Therapeutics, reports the vesting of RSUs and a transfer of shares to a revocable trust.

Anne Nunes, SVP and Chief Operations Officer of Anika Therapeutics, reports the vesting of restricted stock units and shares withheld for tax obligations.

David Colleran, EVP, General Counsel, and Corporate Secretary of Anika Therapeutics, reports the vesting of RSUs and associated stock transactions.

Cheryl Blanchard, CEO of Anika Therapeutics, reports the vesting of RSUs, tax withholding, and a transfer of shares to a revocable trust.

Anne Nunes, SVP and Chief Operations Officer of Anika Therapeutics, reports the vesting of restricted stock units and shares withheld for tax obligations.

Director Susan Vogt reports acquiring and disposing of Anika Therapeutics common stock on July 9, 2024, according to a Form 4 filing.